Hunterian Medicine develops a patented CRISPR delivery platform using a bidirectional promoter to efficiently package gene-editing tools within a single adeno-associated virus (AAV). This technology addresses the challenge of delivering CRISPR therapeutics for over 95% of genetic diseases that currently lack FDA-approved treatments.
Funding
$300K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The delivery of CRISPR-based therapeutics to target cells has been a significant barrier to widespread development, particularly for the over 95% of genetic diseases lacking FDA-approved treatments. The limited packaging capacity of adeno-associated virus (AAV), a safe and effective delivery vehicle, restricts the size of CRISPR components that can be delivered, hindering effective gene editing.
Solution
Hunterian Medicine has developed a patented CRISPR delivery platform that utilizes a novel bidirectional promoter to overcome the size constraints of AAV. This "2-for-1" genetic control element reduces the space required for in vivo expression of CRISPR components, enabling efficient packaging and delivery within a single AAV. By freeing up space within the AAV, the platform facilitates the development of safer and more effective CRISPR-based therapeutics with the potential to target a significantly expanded range of regions in the human genome. This technology aims to provide permanent, one-time cures by directly correcting DNA mutations, addressing the root cause of genetic disorders.
Target Audience
Hunterian Medicine's primary target audience includes researchers and pharmaceutical companies focused on developing gene-editing therapies for genetic diseases.
Features
- Patented bidirectional promoter technology for efficient CRISPR packaging within AAV
- Enables delivery of CRISPR components within the limited packaging capacity of AAV
- Facilitates the development of safer and more effective CRISPR-based therapeutics
- Potential to target a significantly expanded range of regions in the human genome compared to existing technologies
- AAV delivery vehicle with a history of safety, efficacy, and lack of toxicity